A monovalent attenuated serotype 2 bluetongue virus vaccine confers homologous protection in sheep.
An outbreak of bluetongue caused by bluetongue virus serotype 2 virus in certain Mediterranean countries during 1999/2000, presented an opportunity to produce a monovalent type 2 vaccine. Since no data have been published previously on the protection conferred by the current live attenuated bluetongue vaccine strains used in the polyvalent vaccine, a challenge experiment was performed to determine the degree of homologous protection induced by the type 2 vaccine strain. The standard vaccine dose of 5 x 10(4) pfu of vaccine conferred 99.7% protection against clinical disease and no viraemia was detected in the vaccinates.
Hunter
P
P
Onderstepoort Biological Products Ltd, South Africa.
Modumo
J
J
D000818:Animals; D001819:Bluetongue / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D001820:Bluetongue virus / Q000276:immunology*; D012756:Sheep; D012757:Sheep Diseases / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D014611:Vaccination / Q000662:veterinary; D014613:Vaccines, Attenuated; D014765:Viral Vaccines; D014766:Viremia / Q000662:veterinary
D014613:Vaccines, Attenuated; D014765:Viral Vaccines